Orchestra BioMed Holdings, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| OBIO | SLDB | RNA | LXEO | RCKT | WVE | |
|---|---|---|---|---|---|---|
| Market cap | 360.63M | 699.11M | 148.48M | 265.14M | 286.51M | 713.97M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -4.0 | -3.8 | -1.5 | -2.4 | -1.6 | -3.1 |
| Price/book | 18.7 | 2.9 | 0.7 | 1.1 | 0.8 | 1.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +57.48% | +54.69% | −41.15% | −61.64% | −19.20% | −54.06% |
| Today | +7.91% | +3.82% | −0.46% | +3.86% | +3.98% | +1.12% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All OBIO news ›Orchestra BioMed to Detail Pivotal Heart Device Trials
NEW HOPE, PA — Orchestra BioMed Holdings Inc. (Nasdaq: OBIO) will outline clinical development plans and upcoming trial milestones for two cardiovascular technologies at a November 12 investor event in New York City, focusing on treatments…
Piper Sandler: 'We believe investors should start to look at and build positions in Orchestra BioMed (OBIO)'
StreetInsider Piper Sandler: 'We believe investors should start to look at and build positions in Orchestra BioMed (OBIO)' StreetInsider.com Top Tickers, 10/15/2026 - S&P 500 ends higher a
Orchestra BioMed Has A Clearer Trial Timeline But A Demanding Valuation
Orchestra BioMed Stock Has A Clearer Trial Timeline But A Demanding Valuation (OBIO) Seeking Alpha - Orchestra BioMed is rated Hold at $5.72 pending pivotal trial data for its hypertension therapy delivered via pacemaker, with results…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- mychesco.com1
- seekingalpha.com1
- streetinsider.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 3 articles, not a forecast.